- Home
- URGN vs CBL Comparison
URGN vs CBL Comparison
Compare URGN & CBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CBL
- Stock Information
- Founded
- URGN 2004
- CBL 1978
- Country
- URGN United States
- CBL United States
- Employees
- URGN N/A
- CBL N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CBL Real Estate Investment Trusts
- Sector
- URGN Health Care
- CBL Real Estate
- Exchange
- URGN Nasdaq
- CBL Nasdaq
- Market Cap
- URGN 830.4M
- CBL 898.9M
- IPO Year
- URGN 2017
- CBL 1993
- Fundamental
- Price
- URGN $16.82
- CBL $28.94
- Analyst Decision
- URGN Strong Buy
- CBL
- Analyst Count
- URGN 8
- CBL 0
- Target Price
- URGN $28.50
- CBL N/A
- AVG Volume (30 Days)
- URGN 1.2M
- CBL 116.9K
- Earning Date
- URGN 11-05-2025
- CBL 11-10-2025
- Dividend Yield
- URGN N/A
- CBL 6.41%
- EPS Growth
- URGN N/A
- CBL 128.05
- EPS
- URGN N/A
- CBL 2.10
- Revenue
- URGN $94,238,000.00
- CBL $539,452,000.00
- Revenue This Year
- URGN $39.63
- CBL N/A
- Revenue Next Year
- URGN $111.49
- CBL N/A
- P/E Ratio
- URGN N/A
- CBL $13.40
- Revenue Growth
- URGN 10.85
- CBL 2.20
- 52 Week Low
- URGN $3.42
- CBL $21.10
- 52 Week High
- URGN $21.71
- CBL $33.54
- Technical
- Relative Strength Index (RSI)
- URGN 42.97
- CBL 41.43
- Support Level
- URGN $15.86
- CBL $28.05
- Resistance Level
- URGN $17.43
- CBL $30.70
- Average True Range (ATR)
- URGN 1.06
- CBL 0.63
- MACD
- URGN -0.15
- CBL -0.21
- Stochastic Oscillator
- URGN 23.05
- CBL 33.38
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.